Takeda and Amylin formally end rocky global alliance for obesity
This article was originally published in Scrip
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.
You may also be interested in...
Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.